ProQR Therapeutics (PRQR) Capital Expenditures (2013 - 2026)

ProQR Therapeutics has reported Capital Expenditures for 14 years, with the latest figure at $192002.3 in Q1 2026.

• Quarterly Capital Expenditures fell 18.51% year-over-year to $192002.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 39.59% YoY) and the FY2025 annual result came in at $1.2 million, down 21.64% from the prior year.
• Capital Expenditures fell to $192002.3 in Q1 2026 per PRQR's latest filing, from $1.8 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.9 million in Q4 2024 and troughed at -$795216.8 in Q1 2024.
• A 5-year average of $404588.1 and a median of $114327.9 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 809.47% in 2022, then sank 444.76% in 2024.
• Over 5 years, Capital Expenditures stood at $1.5 million in 2022, then jumped by 57.93% to $2.3 million in 2023, then climbed by 25.45% to $2.9 million in 2024, then sank by 38.99% to $1.8 million in 2025, then slumped by 89.11% to $192002.3 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $192002.3, $1.8 million, and -$197570.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.